Web-Based Database as a Tool to Examine Drug–Drug Interactions Involving Transporters

The clinical importance of drug–drug interaction mediated by drug transporters has been gradually recognized; its quantitative prediction and an in silico database of drug–drug interaction have been much wanted. In this chapter, examples of, and prediction methods for, transporter-mediated drug–drug interactions are shown, and a Web-based transporter-mediated drug–drug interaction database in TP-search (http://www.TP-Search.jp/) is also described.

[1]  C. Wandel,et al.  Increased drug delivery to the brain by P‐glycoprotein inhibition , 2000, Clinical pharmacology and therapeutics.

[2]  Yuichi Sugiyama,et al.  Contribution of Organic Anion Transporters to the Renal Uptake of Anionic Compounds and Nucleoside Derivatives in Rat , 2003, Journal of Pharmacology and Experimental Therapeutics.

[3]  Yuichi Sugiyama,et al.  Quantitative Evaluation of the Drug-Drug Interactions between Methotrexate and Nonsteroidal Anti-Inflammatory Drugs in the Renal Uptake Process Based on the Contribution of Organic Anion Transporters and Reduced Folate Carrier , 2004, Journal of Pharmacology and Experimental Therapeutics.

[4]  N. Yasui-Furukori,et al.  Different Effects of Three Transporting Inhibitors, Verapamil, Cimetidine, and Probenecid, on Fexofenadine Pharmacokinetics , 2005, Clinical pharmacology and therapeutics.

[5]  P. Neuvonen,et al.  Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol , 2003, Clinical pharmacology and therapeutics.

[6]  P. Neuvonen,et al.  Effects of orange juice on the pharmacokinetics of atenolol , 2005, European Journal of Clinical Pharmacology.

[7]  G R Wilkinson,et al.  Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. , 1999, Circulation.

[8]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[9]  Kazuya Maeda,et al.  Investigation of the Inhibitory Effects of Various Drugs on the Hepatic Uptake of Fexofenadine in Humans , 2008, Drug Metabolism and Disposition.

[10]  Y. Sugiyama,et al.  Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.

[11]  J. Schellens,et al.  P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. , 1999, Pharmacological research.

[12]  Kazuya Maeda,et al.  Prediction of the Hepatic and Renal Clearance of Transporter Substrates in Rats Using in Vitro Uptake Experiments , 2009, Drug Metabolism and Disposition.

[13]  Jürg Reichen,et al.  The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions , 2001, Clinical pharmacology and therapeutics.

[14]  S. D. de Morais,et al.  Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. , 2004, Chemico-biological interactions.

[15]  Y. Sugiyama,et al.  Method for predicting the risk of drug–drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[16]  K. Maeda,et al.  DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1 , 2006, Drug Metabolism and Disposition.

[17]  Yuichi Sugiyama,et al.  Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. , 2005, Annual review of pharmacology and toxicology.

[18]  Yi Wang,et al.  Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin , 2008, Drug Metabolism and Disposition.

[19]  A. G. Maiche,et al.  ACUTE RENAL FAILURE DUE TO CONCOMITANT ACTION OF METHOTREXATE AND INDOMETHACIN , 1986, The Lancet.

[20]  Yuichi Sugiyama,et al.  A Species Difference in the Transport Activities of H2 Receptor Antagonists by Rat and Human Renal Organic Anion and Cation Transporters , 2005, Journal of Pharmacology and Experimental Therapeutics.

[21]  J. Sahi,et al.  Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034. , 2006, Chemico-biological interactions.

[22]  Yuichi Sugiyama,et al.  Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[23]  P. Neuvonen,et al.  Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. , 2003, British journal of clinical pharmacology.

[24]  L Fritsche,et al.  Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine‐treated kidney transplant recipients , 1999, Clinical pharmacology and therapeutics.

[25]  C. Funk,et al.  Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. , 2001, Molecular pharmacology.

[26]  Wilhelm Kirch,et al.  Grapefruit Juice Ingestion Significantly Reduces Talinolol Bioavailability , 2005, Clinical pharmacology and therapeutics.

[27]  Yuichi Sugiyama,et al.  Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A , 2003, Journal of Pharmacology and Experimental Therapeutics.

[28]  Kazuya Maeda,et al.  Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.

[29]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[30]  A. D. Rodrigues,et al.  Drug-drug interactions , 2001, Atkinson's Principles of Clinical Pharmacology.

[31]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[32]  K. Maeda,et al.  Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans , 2004, Journal of Pharmacology and Experimental Therapeutics.

[33]  Kazuya Maeda,et al.  PREDOMINANT CONTRIBUTION OF OATP1B3 TO THE HEPATIC UPTAKE OF TELMISARTAN, AN ANGIOTENSIN II RECEPTOR ANTAGONIST, IN HUMANS , 2006, Drug Metabolism and Disposition.

[34]  Satohiro Masuda,et al.  Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells , 2009, Journal of Pharmacology and Experimental Therapeutics.

[35]  Kazuya Maeda,et al.  CONTRIBUTION OF OATP (ORGANIC ANION-TRANSPORTING POLYPEPTIDE) FAMILY TRANSPORTERS TO THE HEPATIC UPTAKE OF FEXOFENADINE IN HUMANS , 2005, Drug Metabolism and Disposition.

[36]  Yuichi Sugiyama,et al.  Drug-Drug Interactions Involving the Membrane Transport Process , 2001 .

[37]  P. Dawson,et al.  Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine , 2002, Clinical pharmacology and therapeutics.

[38]  Philip Zocharski,et al.  Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[39]  N. Ozawa,et al.  Transporter Database, TP-Search: A Web-Accessible Comprehensive Database for Research in Pharmacokinetics of Drugs , 2004, Pharmaceutical Research.

[40]  C. Fichtenbaum,et al.  Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin: Results of AIDS Clinical Trials Group 5108 Study , 2005, Journal of acquired immune deficiency syndromes.

[41]  Y. Sugiyama,et al.  Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. , 2001, The Journal of pharmacology and experimental therapeutics.

[42]  Hiroaki Yuasa,et al.  The Inhibition of Human Multidrug and Toxin Extrusion 1 Is Involved in the Drug-Drug Interaction Caused by Cimetidine , 2009, Drug Metabolism and Disposition.

[43]  H L McLeod,et al.  Clinically relevant drug-drug interactions in oncology. , 1998, British journal of clinical pharmacology.

[44]  Kazuya Maeda,et al.  In Vitro–In Vivo Scale‐up of Drug Transport Activities , 2006 .